Same Diagnosis, Same First-Line Drug — Except the Standard First-Line Isn’t Right for Everyone
Both patients have the same violent-dream diagnosis clonazepam is built for. What changes the answer isn’t the diagnosis — it’s what else is true about each of them by the time they reach this age.
E.R., a 69-year-old woman, retired four years ago from a long career as a hospital nurse and now spends much of her time gardening and volunteering at her church’s food pantry twice a week — a full, active retirement she describes with real satisfaction. Her husband first raised the concern that brought her in: for roughly a year, she has occasionally cried out and thrown a punch in her sleep, always corresponding, when he wakes her, to a dream in which she’s protecting someone or fighting off a threat. There has been no injury to either of them so far, but the frequency has crept up over the past few months, now several nights a week rather than the occasional episode it started as.
She has no cardiopulmonary disease, no history of falls, and no cognitive complaints from herself or her husband; her only chronic condition is well-controlled hypothyroidism on stable levothyroxine, and she takes no other medications. A polysomnogram confirmed REM sleep without atonia consistent with RBD, with no coexisting obstructive sleep apnea or other sleep pathology identified on the same study. Functionally she is entirely independent, drives herself everywhere including at night, and her gait and balance on today’s exam are unremarkable for her age.
She is here today specifically because her husband, more worried than she is, wants “whatever the standard treatment is” and asked directly whether that’s the benzodiazepine he read about online, or something gentler given her age — a question she says she hasn’t thought much about herself, trusting the team to recommend whatever is actually appropriate for her.
For her specifically, I don’t think age alone should override clonazepam as the default. She has none of the factors that usually make clinicians cautious about benzodiazepines in older adults — no fall history, no gait abnormality, no cognitive concern, no coexisting OSA that a GABAergic drug could worsen. Clonazepam remains, by long clinical practice, the most-studied and generally most effective agent for RBD symptom control, typically at 0.5–1 mg at bedtime.
Her age is a real variable to consider, but it isn’t, on its own, a contraindication when none of the specific risk factors that actually matter are present.
I’d agree, with one addition rather than a real objection. I’d still want a slightly more cautious starting dose than a younger adult might get — 0.25–0.5 mg rather than reflexively starting at 1 mg — given that benzodiazepine pharmacokinetics still shift somewhat with age even in an otherwise low-risk patient, and I’d want a specific fall-risk recheck at her follow-up rather than assuming today’s clean exam holds indefinitely.
Agreed: clonazepam started at an age-adjusted but still standard-first-line dose, with a fall-risk recheck scheduled at follow-up rather than assumed unnecessary based on today’s exam alone.
F.G., a 77-year-old man, lives with his adult daughter after a fall four months ago that fractured his wrist — his second fall in about a year, though the first was minor and he never sought care for it. He was a long-haul truck driver for most of his working life and has moderate obstructive sleep apnea, diagnosed two years ago and treated inconsistently; he owns a CPAP machine but by his daughter’s account uses it “maybe half the nights,” finding the mask uncomfortable. He has mild, well-documented gait unsteadiness that his primary care physician has been monitoring, attributed so far to a combination of deconditioning and early osteoarthritis in both knees, without a specific neurologic diagnosis.
His daughter brought him in after several months of him lashing out during sleep — once striking the nightstand hard enough to knock a lamp over, another time grabbing at the air and yelling what sounded like a name from his trucking days. A polysomnogram confirmed REM sleep without atonia and RBD-consistent behavior, alongside his already-known moderate OSA on the same study, not well controlled given his inconsistent CPAP use. He has no other psychiatric history, takes amlodipine for hypertension, and no other regular medications.
He is here today somewhat reluctantly, brought by his daughter rather than seeking care himself, and when clonazepam was mentioned as a possible treatment he recalled, unprompted, that a friend his age had a bad fall after starting a similar medication years ago — a memory that has made him wary before anyone had even explained his own options.
For him, I don’t think clonazepam is the reasonable default the way it was for E.R. He has two independent, well-documented risk factors clonazepam can make worse: a real fall history — two falls in a year, one resulting in a fracture — and moderate OSA that is currently poorly controlled given his inconsistent CPAP use. Benzodiazepines increase fall risk through sedation and impaired balance, and they can worsen upper-airway collapse in OSA by reducing pharyngeal muscle tone during sleep.
Melatonin, by contrast, has real if more modest evidence for RBD symptom reduction — McGrane and colleagues’ review of the melatonin-in-RBD literature found consistent, if smaller, benefit across the available open-label and case-series data — carries essentially no fall-risk or respiratory-depressant profile, and is the option specifically favored in exactly this combination of older age, fall history, and comorbid OSA.
You’re right that his fall history and OSA are real, specific reasons to avoid clonazepam here — I’m not disputing either risk factor, and I agree neither is present for E.R. the same way. But I want to be honest that melatonin’s evidence base for RBD is genuinely thinner than clonazepam’s; it’s a reasonable and safer first try given his specific risks, not a drug we should present to him or his daughter as equally effective.
I’d start melatonin, address his CPAP adherence directly since untreated OSA is itself worsening his overall sleep quality independent of the RBD question, and set an explicit follow-up point to reassess if melatonin alone doesn’t adequately control his symptoms — at which point his actual fall risk and OSA control, not a blanket rule, should guide whether a more cautious, monitored benzodiazepine trial becomes reasonable after all.
Agreed: melatonin started as first-line given his specific, documented risk factors, alongside a direct effort to improve his CPAP adherence. Not agreed: how long to wait before considering a cautious, monitored clonazepam trial if melatonin alone doesn’t adequately control his symptoms — left as a follow-up decision rather than fixed today.